Natera, Inc. NTRA 深 滬
已收盤 02-06 16:00:00 美东时间
203.04
+5.960
+3.02%
華盛通- 最 高203.68
- 今 開199.73
- 成交量 156.40万股
- 最 低 194.02
- 昨 收 197.08
- 總市值 283.14亿
- 52周最高 256.36
- 市盈率 靜 --
- 換手率 1.12%
- 52周最低 125.38
- 委 比 73.54%
- 總股本 1.39亿
- 歷史最高 256.36
- 量 比 1.10
- 振 幅 4.90%
- 歷史最低 6.52
- 每 手 1
- 風險率 33.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Natera shares are trading higher after the company announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay in colorectal cancer.
Natera shares are trading higher after the company announced the publication in...
01-22 04:00
Natera Advances Molecular Residual Disease-Based Risk Stratification With New Multi-Model
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to
01-13 21:10
Reported Earlier, Natera Reports Preliminary Q4 2025 Revenue Of $660M (Up 39% YoY) And Preliminary Full-Year Revenue Of $2.3B (Up 35% YoY), Fueled By Signatera Growth
2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera's financial outlookAdditional business updates will be presented at the 44th
01-12 14:39
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Guggenheim Maintains Buy on Natera, Raises Price Target to $270
Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $230 to $270.
01-06 01:03
夜读 | 2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技！
2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技，特斯拉仍为最大持仓！布局详情>>
01-05 23:59
Natera Highlights Signatera Study In Nature Communications
The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT). These cancers often leave behind substantial residual disease and
2025-12-16 21:09
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
